Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Baccarani
M
M
Department of Hematology and Oncology 'L. and A. Seragnoli', University of Bologna, S. Orsola-Malpighi Hospital, Italy.
Dreyling
M
M
D001549:Benzamides; D020732:Cytogenetic Analysis; D005060:Europe / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007167:Immunotherapy; D017404:In Situ Hybridization, Fluorescence; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D007964:Leukocytosis / Q000473:pathology; D009367:Neoplasm Staging; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018570:Risk Assessment; D013922:Thrombocytosis / Q000473:pathology; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate